With box warnings

Without box warnings

Branded

Generic

4 results

adcetris
(brentuximab vedotin)
SEAGEN INC.
Usage: ADCETRIS is indicated for treating adult and pediatric patients with previously untreated or relapsed classical Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL), as well as for consolidation post-transplant in high-risk cHL. It is used in combination with specific chemotherapy regimens.
padcev
(ENFORTUMAB VEDOTIN)
SEAGEN INC.
Usage: PADCEV® is indicated for adults with locally advanced or metastatic urothelial cancer (mUC). It can be used in combination with pembrolizumab or as a single agent for patients who have previously received PD-1/PD-L1 inhibitors and platinum-based chemotherapy, or are ineligible for cisplatin-containing chemotherapy.
tivdak
(tisotumab vedotin)
Seagen Inc.
Usage: TIVDAK® is indicated for adult patients with recurrent or metastatic cervical cancer that has progressed following chemotherapy.
tukysa
(tucatinib)
SEAGEN INC.
Usage: TUKYSA is indicated for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, and for those with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that progressed after standard chemotherapy. It requires prior anti-HER2 therapy for approval.

SEAGEN INC. drugs

adcetris